SLAMF7 Polyclonal Antibody, PE-Cy5.5 Conjugated
Product Specifications
Background
SLAMF7 contains one Ig-like C2-type (immunoglobulin-like) domain. Isoform 1 mediates NK cell activation through a SAP-independent extracellular signal-regulated ERK-mediated pathway. It may play a role in lymphocyte adhesion. Isoform 3 does not mediate any activation. SAP can bind the cytoplasmic tail of isoform 1 when phosphorylated in the presence of Fyn (in vitro) . SLAMF7 is expressed in spleen, lymph node, peripheral blood leukocytes, bone marrow, small intestine, stomach, appendix, lung and trachea. Expression was detected in NK cells, activated B-cells, NK-cell line but not in promyelocytic, B-, or T-cell lines. The isoform 3 is expressed at much lower level than isoform 1. There are three named isoforms.
Synonyms
19A; 19A24 protein; CD 319; CD2 like receptor activating cytotoxic cells; CD2 subset 1; CD319; CD319 antigen; CRACC; CS1; Membrane protein FOAP 12; Novel Ly9; Novel LY9 lymphocyte antigen 9 like protein; Protein 19A; SLAM family member 7; SLAMF 7.
Swiss Prot
Q9NQ25
Cellular Locus
Cell membrane
Host
Rabbit
Immunogen
51-160/335
Target
SLAMF7
Clonality
Polyclonal
Isotype
IgG
Conjugation
PE-Cy5.5
Source
KLH conjugated synthetic peptide derived from human SLAMF7
Applications
WB, FCM
Purification
Purified by Protein A.
Excitation Emission
488nm/694nm
Concentration
1µg/µl
Dilution
WB (1:300-5000), FCM (1:20-100)
Buffer
Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Modification
Unmodified
Storage Conditions
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Predicted Cross Reactivity
Human, Mouse, Rat, Cow
More Discoveries
Explore Other Products
Browse additional items from our catalog
